Lyra therapeutics reports first quarter 2025 financial results and provides corporate update

– phase 3 results from enlighten 2 pivotal phase 3 trial of lyr 210 in chronic rhinosinusitis (crs) expected in q2 2025 – – phase 3 results from enlighten 2 pivotal phase 3 trial of lyr 210 in chronic rhinosinusitis (crs) expected in q2 2025 –

CRS Ratings Summary

CRS Quant Ranking